A detailed history of Ubs Asset Management Americas Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 2,441,468 shares of VRTX stock, worth $1.13 Billion. This represents 0.3% of its overall portfolio holdings.

Number of Shares
2,441,468
Previous 2,584,327 5.53%
Holding current value
$1.13 Billion
Previous $1.21 Billion 6.26%
% of portfolio
0.3%
Previous 0.35%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$460.0 - $505.78 $65.7 Million - $72.3 Million
-142,859 Reduced 5.53%
2,441,468 $1.14 Billion
Q2 2024

Aug 13, 2024

BUY
$392.81 - $485.53 $54.3 Million - $67.1 Million
138,275 Added 5.65%
2,584,327 $1.21 Billion
Q1 2024

May 15, 2024

SELL
$407.69 - $446.08 $62.7 Million - $68.6 Million
-153,852 Reduced 5.92%
2,446,052 $1.02 Billion
Q4 2023

Feb 14, 2024

SELL
$343.0 - $410.68 $59.6 Million - $71.4 Million
-173,895 Reduced 6.27%
2,599,904 $1.06 Billion
Q3 2023

Nov 13, 2023

SELL
$338.18 - $362.46 $12.8 Million - $13.7 Million
-37,932 Reduced 1.35%
2,773,799 $965 Million
Q1 2023

May 15, 2023

SELL
$283.23 - $323.1 $33.3 Million - $38 Million
-117,685 Reduced 4.02%
2,811,731 $886 Million
Q4 2022

Feb 14, 2023

SELL
$285.76 - $321.48 $65.5 Million - $73.7 Million
-229,276 Reduced 7.26%
2,929,416 $846 Million
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $9.96 Million - $11.1 Million
36,378 Added 1.17%
3,158,692 $915 Million
Q2 2022

Aug 12, 2022

SELL
$234.96 - $292.55 $4 Million - $4.98 Million
-17,023 Reduced 0.54%
3,122,314 $880 Million
Q1 2022

May 16, 2022

SELL
$221.42 - $260.97 $83 Million - $97.8 Million
-374,894 Reduced 10.67%
3,139,337 $819 Million
Q4 2021

Feb 14, 2022

BUY
$177.01 - $223.45 $134 Million - $169 Million
755,378 Added 27.38%
3,514,231 $772 Million
Q3 2021

Nov 15, 2021

BUY
$181.39 - $202.99 $55.7 Million - $62.4 Million
307,208 Added 12.53%
2,758,853 $500 Million
Q2 2021

Aug 16, 2021

BUY
$187.49 - $221.1 $71.6 Million - $84.5 Million
382,126 Added 18.46%
2,451,645 $494 Million
Q1 2021

May 14, 2021

SELL
$207.02 - $241.31 $3.65 Million - $4.26 Million
-17,648 Reduced 0.85%
2,069,519 $445 Million
Q4 2020

Mar 01, 2021

BUY
$207.01 - $276.09 $97.9 Million - $131 Million
473,124 Added 29.31%
2,087,167 $493 Million
Q3 2020

Nov 13, 2020

BUY
$255.65 - $303.1 $15.5 Million - $18.3 Million
60,494 Added 3.89%
1,614,043 $439 Million
Q2 2020

Aug 14, 2020

BUY
$225.48 - $295.8 $33.9 Million - $44.4 Million
150,223 Added 10.7%
1,553,549 $451 Million
Q1 2020

May 15, 2020

BUY
$199.77 - $247.81 $9.29 Million - $11.5 Million
46,491 Added 3.43%
1,403,326 $334 Million
Q4 2019

Feb 14, 2020

SELL
$166.71 - $223.91 $4.68 Million - $6.28 Million
-28,058 Reduced 2.03%
1,356,835 $297 Million
Q3 2019

Nov 14, 2019

SELL
$166.23 - $187.09 $1.45 Million - $1.63 Million
-8,710 Reduced 0.62%
1,384,893 $235 Million
Q2 2019

Aug 15, 2019

BUY
$164.61 - $190.37 $6.04 Million - $6.98 Million
36,663 Added 2.7%
1,393,603 $0
Q1 2019

May 14, 2019

SELL
$163.73 - $194.7 $415,710 - $494,343
-2,539 Reduced 0.19%
1,356,940 $0
Q4 2018

Feb 13, 2019

BUY
$151.91 - $192.21 $5.57 Million - $7.04 Million
36,635 Added 2.77%
1,359,479 $225 Million
Q3 2018

Nov 14, 2018

SELL
$167.73 - $192.74 $6.19 Million - $7.12 Million
-36,920 Reduced 2.72%
1,322,844 $0
Q2 2018

Aug 14, 2018

BUY
$145.72 - $169.96 $18.8 Million - $21.9 Million
128,779 Added 10.46%
1,359,764 $0
Q1 2018

May 14, 2018

SELL
$151.6 - $177.13 $1.63 Million - $1.9 Million
-10,748 Reduced 0.87%
1,230,985 $0
Q4 2017

Feb 09, 2018

BUY
$137.28 - $155.55 $17 Million - $19.3 Million
123,996 Added 11.09%
1,241,733 $0
Q3 2017

Nov 13, 2017

BUY
$148.13 - $162.24 $166 Million - $181 Million
1,117,737
1,117,737 $0

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.